Consensus revenue estimates fall to US$7.57m
The consensus outlook for revenues in 2021 has deteriorated.
- 2021 revenue forecast decreased from US$9.14m to US$7.57m.
- Forecast losses increased from -US$7.00 to -US$7.33 per share.
- Biotechs industry in the US expected to see average net income decline 21% next year.
- Consensus price target down from US$87.53 to US$83.00.
- Share price was steady at US$43.36 over the past week.